Showing 2131-2140 of 4307 results for "".
- Aclaris Initiates Phase 2b Trials of A-101 for Topical Treatment of Common Wartshttps://practicaldermatology.com/news/aclaris-initiates-phase-2b-trials-of-a-101-for-topical-treatment-of-common-warts/2458135/Aclaris Therapeutics, Inc. has initiated two Phase 2 clinical trials to evaluate A-101 45% topical solution (A-101 45%), an investigational drug for the treatment of common warts (verruca vulgaris). Over 22 million Americans have common warts, but there are currently no FDA-approved prescription
- Common Soap Ingredient May Alter Skin's Wettabilityhttps://practicaldermatology.com/news/common-soap-ingredient-may-alter-skins-wettability/2458139/New research suggests that it is possible to alter the wettability of your skin using an ingredient commonly found in cosmetic cleaners. In a recent study, Guy German, PhD, an assistant professor of biomedical engineering at Binghamton University, State University of New York, along with
- Wontech's Pico Laser Gets FDA Nodhttps://practicaldermatology.com/news/wontechs-pico-laser-gets-fda-nod/2458146/The U.S. Food and Drug Administration (FDA) cleared WONTECH’s picosecond laser device for tattoo removal. PICOCARE removes tattoos in various colors in less time with 1064nm, 532nm, 595nm, and 660nm wavelengths and selectively removes pigment par
- Stratpharma AG's Wound Care Products Come to the UShttps://practicaldermatology.com/news/stratpharma-ags-wound-care-products-come-to-the-us/2458148/Stratpharma’s wound care and scar management portfolio is now available in the US, according to Stratpharma Inc. USA, a U.S. subsidiary of Stratpharma AG, the Swiss company. The portfolio include
- Some Hair Products May Up Breast Cancer Risk in Certain Womenhttps://practicaldermatology.com/news/some-hair-products-may-up-breast-cancer-risk-in-some-women/2458156/Use of hair dyes may increase risk for breast cancer among certain women, new research suggests. Specifically, dark brown or black hair dye was associated with a 51 percent increased overall risk of developing breast cancer among African American women, and a 72 percent increased risk of
- Coppertone Whips Up Excitement About New Sunscreen Linehttps://practicaldermatology.com/news/coppertone-whips-up-excitement-about-new-sunscreen-line/2458152/Coppertone is going all out to launch their new Whipped line, available in both CLEARLYSheer® and WaterBABIES® Pure & Simple formulas, including partnering with beauty influencers and the Skin Cancer Foundation. The brand is promot
- PsA Patients Failing Anti-TNF Drugs May Do Well on Taltzhttps://practicaldermatology.com/news/psa-patients-who-fail-anti-tnf-drugs-may-do-well-on-taltz/2458154/New data show that Taltz (ixekizumab) improved the signs and symptoms of active psoriatic arthritis (PsA) in patients who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors treated. Eli Lilly has filed a supple
- And Then There Were Three: Alma Lasers Inc. Hair Removal Platform Now Comprises Three Wavelengthshttps://practicaldermatology.com/news/and-then-there-were-three-alma-lasers-inc-hair-removal-platform-now-comprises-three-wavelengths/2458158/Alma Lasers now offers 1064 Nd: YAG capabilities along with 810nm and 755nm on its Soprano ICE platform, allowing users to better match wavelength to hair removal patient. Alma added Alexandrite technology to its Soprano ICE platform in 2014 for
- FDA Warns Public About Black Henna Tattoo Riskshttps://practicaldermatology.com/news/fda-warns-public-about-black-henna-tattoo-risks/2458159/Black henna temporary tattoos can cause serious skin reactions, the US Food and Drug Administration (FDA) warns. For centuries, traditional henna, a reddish-brown plant extract, has been used to dye skin, hair, and fingernails in parts of Asia and Northern Africa. Henna is
- Retailers Charge Women More Than Men for Minoxidilhttps://practicaldermatology.com/news/retailers-charge-women-more-than-men-for-minoxidil/2458163/Women pay an average of 40 percent more than men for minoxidil foams, according to a new analysis from researchers at the Perelman School of Medicine at the University of Pennsylvania in JAMA Dermatology</